RxDoctor Payments Data

Tangela Hardy, NP

Nurse Practitioner · North Chesterfield, VANPI 1184009714

Payments from drug & device makers

$2,525in general payments, 2019–2025

Across 28 payments — averaging $90.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$389
  • Amgen$253
  • Boehringer Ingelheim$198
  • AbbVie$193
  • Johnson & Johnson$187
  • Lundbeck LLC$180
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$2,525100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,525 in reported general payments places this provider in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$160,421
Medicare patients
241
Services billed
1,341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$82,575
XareltoRivaroxaban31$22,322
MyrbetriqMirabegron40$19,046
EntrestoSacubitril/Valsartan21$15,644
TrulicityDulaglutide14$14,495
CreonLipase/Protease/Amylase11$11,146
Breo ElliptaFluticasone/Vilanterol19$8,050
NamzaricMemantine Hcl/Donepezil Hcl11$6,982
Memantine Hcl179$5,619
LumiganBimatoprost12$3,976
Donepezil Hcl160$3,478
Levothyroxine Sodium275$3,324
Aspirin-Dipyridamole ErAspirin/Dipyridamole12$3,190
Atorvastatin Calcium236$3,130
Verapamil Er PmVerapamil Hcl13$2,798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$105$82,575138 claims
Johnson & JohnsonXarelto$187$22,32231 claims
AbbVieCreon, Namzaric, Lumigan$193$22,10434 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in North Chesterfield

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →